| 证券代 | 证券简 | 今日涨跌幅 | 今日换手率 | 五日均线 | 最新价 | 乖离率 | | --- | --- | --- | --- | --- | --- | --- | | 码 | 称 | （%） | （%） | （元） | （元） | （%） | | 688206 | 概伦电 子 | 20.01 | 10.70 | 24.22 | 27.77 | 14.65 | | 301005 | 超捷股 份 | 19.99 | 12.04 | 31.98 | 36.61 | 14.49 | | 300698 | 万马科 技 | 16.42 | 15.00 | 35.81 | 40.35 | 12.67 | | 836270 | 天铭科 技 | 15.70 | 7.99 | 17.33 | 19.31 | 11.40 | | 301095 | 广立微 | 14.19 | 9.62 | 48.77 | 53.99 | 10.70 | | 301322 | 绿通科 技 | 13.58 | 5.63 | 26.67 | 29.44 | 10.38 | | 300149 | 睿智医 药 | 20.06 | 12. ...

Group 1 - The pharmaceutical sector is experiencing renewed activity, particularly in CRO, innovative drugs, and medical services, with significant gains in related ETFs [1] - The Biopharmaceutical ETF (159859) rose by 1.7%, with trading volume exceeding 50 million yuan, while the Innovative Drug ETF Tianhong (517380) increased by 1.66%, with several constituent stocks rising over 5% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ) and is the largest product in its category, also offering a connecting fund [1] Group 2 - The ASCO annual meeting, a major platform for biopharmaceutical companies to present clinical research results, will take place from May 30 to June 3, 2025, in Chicago and online [2] - The innovative drug sector is highlighted as a key focus for the year, with attention on areas such as anti-tumor, autoimmune, GLP-1, stem cells, and gene therapy, alongside domestic pharmaceutical consumption and medical aesthetics [2] - The innovative drug sector is expected to maintain its growth, supported by policy, global competitiveness, and improving fundamentals, with a potential recovery in demand anticipated by 2025 [2]

A股CRO概念持续拉升，睿智医药涨停，美迪西涨超8%，成都先导涨近7%，联化科技、凯莱英等跟 涨。 ...

Market Overview - The overall market experienced a slight decline with the Shanghai Composite Index down 0.02%, the Shenzhen Component down 0.26%, and the ChiNext Index down 0.31%, indicating cautious market sentiment with over 3,400 stocks in the red [3][4] Key Investment Themes Environmental Protection and Energy - The solid waste treatment and combustible ice sectors saw strong gains, with stocks like Yuhua Tian and Boschke hitting the daily limit of 20%. This surge is driven by enhanced environmental policies and new regulations on industrial solid waste management [4] - Companies in this sector are expected to have a policy moat and performance outlook, suggesting that investors should consider gradual accumulation during pullbacks, especially in leading firms with technological barriers [4] Consumer Recovery - The food and beverage sector showed activity, with stocks like Huanlejia reaching a 20% limit up, driven by the upcoming summer consumption peak and anticipated price increases in some consumer goods [4] - However, the pharmaceutical sector faced collective adjustments, with companies like Ruizhi Pharmaceutical and Xue Rong Biological leading the decline due to rising expectations for centralized procurement and some companies' performance falling short of expectations [4] Technology Sector - The controlled nuclear fusion concept gained traction, with stocks like Libote and Rongfa Nuclear Power hitting the daily limit. This area is part of the new energy sector, with strong expectations for technological breakthroughs and a willingness from investors to pay premiums [5] - Conversely, the cross-border e-commerce and chemical sectors experienced pullbacks, particularly in the epoxy propane segment, primarily due to fluctuations in raw material prices [5] Market Sentiment and Strategy - Investors are advised to focus on structural opportunities concentrated in policy-driven and performance-reliable sectors, rather than being swayed by daily market fluctuations [6] - There was a slight inflow of northbound capital, but significant divergence among domestic investors suggests the need to monitor future volume expansion [6] - Maintaining a controlled position is recommended while waiting for market shifts, with strong support around the 3,300-point level for the Shanghai Composite Index [7]

证券代码：300149 证券简称：睿智医药 公告编号：2025-43 睿智医药科技股份有限公司 关于召开 2024 年年度股东会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日在巨 潮资讯网（www.cninfo.com.cn）上披露《关于 2024 年年度股东会增加临时提案、 调整会议召开时间暨股东会补充通知的公告》（公告编号：2025-38），公司定于 投票与网络投票相结合的方式，为切实保护广大投资者的合法权益，方便公司股 东行使表决权，现将本次股东会的有关事宜提示如下： 一、召开会议基本情况 定召开 2024 年年度股东会，召集的程序符合《深圳证券交易所创业板股票上市规 则》等相关法律法规和《公司章程》的规定。 现场会议时间：2025 年 5 月 30 日（星期五）下午 14:00 网络投票时间：2025 年 5 月 30 日。其中，通过深圳证券交易系统进行网络 投票的具体时间为 2025 年 5 月 30 日上午 9:15-9:25，9:30-11:30，下午 13: ...

证券代码：300149 证券简称：睿智医药 公告编号：2025-43 睿智医药科技股份有限公司 关于召开 2024 年年度股东会的提示性公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有虚假记载、 误导性陈述或重大遗漏。 睿智医药科技股份有限公司（以下简称"公司"）于 2025 年 5 月 19 日在巨 潮资讯网（www.cninfo.com.cn）上披露《关于 2024 年年度股东会增加临时提案、 调整会议召开时间暨股东会补充通知的公告》（公告编号：2025-38），公司定于 2025 年 5 月 30 日（星期五）召开公司 2024 年年度股东会，本次会议将采取现场 投票与网络投票相结合的方式，为切实保护广大投资者的合法权益，方便公司股 东行使表决权，现将本次股东会的有关事宜提示如下： 一、召开会议基本情况 1、会议届次：2024 年年度股东会 2、召集人：公司董事会 3、会议召开的合法、合规性：经公司第六届董事会第六次会议审议通过，决 定召开 2024 年年度股东会，召集的程序符合《深圳证券交易所创业板股票上市规 则》等相关法律法规和《公司章程》的规定。 4、现场会议召开时间 现场会议时间： ...

Group 1 - The innovative drug concept stocks are experiencing a downturn, with several companies seeing declines of over 5% [1] - Notable companies affected include Sanofi, Haisun Pharmaceutical, Huisheng Biological, Rejing Biological, Haichuang Pharmaceutical, and Ruizhi Pharmaceutical [1] - Other companies such as Saiseng Pharmaceutical and Hasan Union are also following the downward trend [1]

Group 1 - The Shanghai Composite Index turned positive on May 27, with the Biopharmaceutical ETF (159859) rising by 0.28% at the time of reporting [1] - Notable gainers within the Biopharmaceutical ETF included Dizhe Pharmaceutical-U, which increased by over 3%, along with Teva Biopharmaceuticals, Kailaiying, and Wantai Biological Pharmacy [1] - The Innovative Drug ETF Tianhong (517380) saw a decline of 0.33%, with Zhejiang Pharmaceutical rising by over 3%, while Ruizhi Pharmaceutical dropped by 3% [1] Group 2 - On May 26, the Biopharmaceutical ETF (159859) experienced a net inflow of 35.36 million yuan despite a drop of 0.57%, while the Innovative Drug ETF Tianhong (517380) had a net inflow of 3.6 million yuan despite a decline of 1.64% [1] - The Biopharmaceutical ETF closely tracks the National Biopharmaceutical Index (399441.SZ), which includes the top 30 securities in the biopharmaceutical sector based on market capitalization and liquidity [1] - The Innovative Drug ETF Tianhong, launched in 2021, has a scale of 389 million yuan as of May 26, and is the only product covering the entire market for the "Hengsheng Huasheng Hong Kong Innovative Drug Selected 50" index [2] Group 3 - Minsheng Securities remains optimistic about the pharmaceutical sector, particularly in the innovative drug and new consumption areas, highlighting ongoing catalysts in the innovative drug sector [2] - Key focus areas for the innovative drug sector include anti-tumor, autoimmune, GLP-1, stem cell, and gene therapy directions, along with an emphasis on domestic production and medical consumption, especially in the beauty sector [2]

Core Viewpoint - The stock price of Giant Bio (HK02367) experienced a significant decline following allegations of product fraud related to its brand, Kefu Mei, which led to a public statement denying the accusations and asserting compliance with regulatory standards [9][10]. Group 1: Company Performance - As of May 26, Giant Bio's stock opened with a drop exceeding 8%, later narrowing to a decline of 3.52% [1]. - The company's market capitalization is approximately 80 billion HKD [11]. - Kefu Mei, a brand under Giant Bio, reported sales revenue exceeding 4.5 billion CNY in 2024, reflecting a year-on-year growth of 62.9% [10]. Group 2: Industry Context - The A-share market saw a collective decline in stocks related to recombinant protein, with notable drops in companies such as Ruizhi Pharmaceutical and Sanofi Guojian, each falling nearly 6% [2]. - The market reaction indicates a broader concern regarding the credibility of companies in the recombinant protein sector following the allegations against Giant Bio [2].

Core Viewpoint - The A-share pharmaceutical sector is experiencing significant fluctuations, with notable declines in several companies' stock prices, indicating a broader market adjustment in this industry [1] Company Summary - Haichen Pharmaceutical has seen its stock price drop by over 10% [1] - Key competitors such as Keyuan Pharmaceutical and Tuoxin Pharmaceutical have also faced declines, with drops exceeding 8% [1] - Other companies in the sector, including Duori Pharmaceutical, Ruizhi Pharmaceutical, and Nuotai Biological, are also experiencing downward trends in their stock prices [1]